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Abstract: Aim: to analyze the signaling pathways involved in H₂O₂ vascular responses in
hypertension. Methods: Vascular function, thromboxane A₂ (TXA₂) production,
oxidative stress and protein expression were determined in mesenteric resistance
arteries (MRA) from hypertensive (SHR) and normotensive WKY rats. Results: H₂O₂
and the TP agonist U46619 induced greater contractile responses in MRA from SHR
than WKY. Moreover H₂O₂increased TXA₂production more in SHR than in WKY. The c-
Src inhibitor PP1 reduced H₂O₂- and U46619-induced contraction and TXA₂ release in
both strains. The ERK1/2 inhibitor PD98059 reduced H₂O₂but not U46619-induced
contraction only in SHR arteries. The Rho Kinase inhibitor Y26372 reduced H₂O₂and
U46619-induced contractions only in SHR arteries. Basal c-Src, ERK1/2 and Rho
Kinase expression were greater in MRA from SHR than WKY. In SHR, the combination
of PD98059 with the TP antagonist SQ29548 but not with Y27632, inhibited the
H₂O₂contraction more than each inhibitor alone. H₂O₂and U46619 increased NAD(P)H
Oxidase activity and O₂.- production and decreased mitochondrial membrane potential
in vessels from SHR. The effects induced by H₂O₂were abolished by inhibitors of
TXA₂synthase, ERK1/2 and c-Src. The mitochondrial antioxidant mitoTEMPO reduced
H₂O₂-induced contraction and NAD(P)H Oxidase activation. Conclusions: In arteries
from WKY, c-Src mediates H₂O₂ contractile responses by modulating TXA₂release and
TXA₂ effect. In SHR, H₂O₂contraction is mediated by c-Src-dependent TXA₂ release
which further activates Rho Kinase, c-Src and the relationship between mitochondria
and NAD(P)H Oxidase. Moreover, ERK1/2 activation contributes to H₂O₂ contraction in
SHR through effects on mitochondria/NAD(P)H Oxidase.
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Dr. A. Stella 
Executive Editor. Journal of Hypertension 
          
April 1st 2014  
 
Dear Editor, 
It was a pleasure to learn that our Manuscript JH-D-13-00369, entitled "ROLE OF c-
Src, ERK1/2 AND Rho Kinase IN HYDROGEN PEROXIDE INDUCED 
CONTRACTION IN RESISTANCE ARTERIES FROM NORMOTENSIVE AND 
HYPERTENSIVE RATS" by García-Redondo et al. was found interesting although a 
not sufficiently high priority was given. The work has been revised in order to 
accommodate the Reviewer´s suggestions. New experiments regarding: 1) basal 
expression of pc-Src, pERK and RhoKinase, 2) involvement of mitochondrial oxidative 
stress in H2O2 responses, 3) the role of TXA2 in the relationship between mitochondria 
and NADHPH oxidase, and 4) measurement of ROS production, have been performed 
as suggested. Accordingly, the manuscript and figures have undergone major changes 
and the title has been changed. In addition, new authors have been added to the 
manuscript.   
We affirm that the present study is not under consideration by another journal, and that 
no part of the material has been published elsewhere. All persons acknowledged have 
seen and approved the mention of their name in the paper. We also state that there is no 
conflict of interest.  
We hope that the new version of the manuscript fulfills all the requirements for its 
publication in Journal of Hypertension. Nevertheless, if anything needs further 
clarification, please do not hesitate to contact us. 
Sincerely yours, 
   
Dr. Ana M. Briones 
Dpto. Farmacología y Terapéutica 
Facultad de Medicina.UAM 
C/ Arzobispo Morcillo, 28029, Madrid 
Phone: 34 91 497 53 99 
Fax: 00 34 91 497 53 80 
e-mail: ana.briones@uam.es 
 
 
Submission letter
 
 
Answers to Reviewer 1 
We would like to thank the Reviewer for his/her constructive comments. The 
manuscript has undergone changes to include data from new experiments. All concerns 
raised have been addressed and a detailed list of changes made is attached. We believe 
that the paper is significantly improved and hope that it is now acceptable for 
publication. 
 
 I have no major concerns regarding this study apart from a couple of considerations: 
1) The potential "translational" meaning of the observed findings could be more 
clearly addressed and detailed. 
 
The Reviewer raised an interesting aspect. It is now evident from an overwhelming 
amount of experimental and animal studies, that oxidative stress has a role in the 
etiology of hypertension. Unfortunately, data in patients are more varying and still no 
clear picture of this aspect has been drawn. Oxidative stress contributes to key features 
of vascular damage in hypertension, namely endothelial dysfunction, vascular 
remodeling and inflammation. This might be explained, in hypertensive patients, not 
only by the increased ROS bioavailability observed systemically or locally (Lacy et al., 
Hypertension. 2000; 36:878-84), but also by the enhanced redox signaling developed in these 
conditions (Touyz et al., Hypertension. 2001;38:56-64). Our data further build on this notion 
demonstrating that different intracellular pathways are involved in H2O2 signaling in 
normotensive and hypertensive animals. Importantly, some of these pathways have a 
key role in cardiovascular function in pathological conditions. Our data also suggest that 
increased basal expression/activity of these intracellular pathways might sensitize 
vessels to H2O2 actions. Finally, we demonstrate that oxidative stress is an important 
perpetuator of key inflammatory pathways including prostanoids and mitochondria 
which act in relationship to induce vascular dysfunction. How this occurs in 
hypertension in humans requires further investigations. However, improving our 
knowledge of H2O2 signaling at vascular level particularly in pathological conditions, 
will help us to develop more specific or more directed strategies to regulate ROS 
signaling to treat hypertensive vascular damage. Some comments on these aspects have 
been now added in the revised version of the manuscript.   
 
 2) Would the use of a antioxidant (e.g. tempol) provide further information about the 
mechanism explored ? 
 
In our previous study (García-Redondo et al., J Hypertens. 2009 27(9):1814-22) we demonstrated 
that treatment of SHR rats with the superoxide analogue Tempol, normalized the 
increased H2O2 contractile responses observed in SHR. Following Reviewer´s 
recommendations, we have now extended these observations and we have performed 
new experiments (new Figures 4 and 5) that demonstrate that H2O2-derived TXA2 
activates c-Src that participates in mitochondrial ROS production which in turn 
activates NADPH oxidase and modulate vascular H2O2 contraction in small arteries 
from SHR. To our knowledge, this is the first study that demonstrates that prostanoids 
derived from H2O2 participate in the relationship existing between NADPH oxidase and 
mitochondria.  
 
 
 Some minor spelling errors may be corrected (e.g. abstract: trough, etc..). 
 
We apologize for the spelling errors. These have been now corrected through the 
manuscript. 
 Answers to Reviewer 2 
We would like to thank the Reviewer for his/her constructive comments. The 
manuscript has undergone changes to include data from new experiments. All concerns 
raised have been addressed and a detailed list of changes made is attached. We believe 
that the paper is significantly improved and hope that it is now acceptable for 
publication. 
 
 Specific points: 
 
1. The model (Fig. 5) and the conclusions are largely based on the results of the 
myograph studies. The model would be more convincing if direct evidence for ERK1/2 
activation as well as RhoA/ROCK activation could be provided. The study so far 
showed differential dependence on these signalling mechanisms but not differential 
activation (e.g. increased phosphorylation of ROCK substrates or ERK1/2 activation). 
 
We agree with the Reviewer that studies on differential activation of the intracellular 
pathways involved in H2O2 responses would have added more convincing evidences. 
We have tried to perform these experiments by evaluating the effect of H2O2 on ERK1/2 
and c-Src activation in mesenteric resistance arteries. Unfortunately, we have observed 
that basal protein activation was very high and we were not able to see further activation 
in response to H2O2. We believe that this might be due to the fact that dissection of the 
mesenteric resistance arteries takes longer than dissection of other vessels such as aorta 
and therefore, it is possible that spontaneous kinase activation might be occurring. Most 
of the articles evaluating intracellular pathways in response to different stimuli usually 
study effects on isolated cell culture systems (i.e smooth muscle cells or endothelial 
cells) in which the stimulation conditions are well controlled. In fact, in a previous 
article Tabet et al., (J Hypertens. 2005 23(11):2005-12) demonstrated that H2O2 stimulated 
phosphorylation of ERK1/2 in cultured vascular smooth muscle cells being this 
activation greater in SHR than in WKY. We cannot also forget that these intracellular 
signaling pathways are usually activated within few minutes of stimulation. Therefore, 
it is not surprising that kinase activation studies are more difficult to perform in whole 
arteries such as mesenteric resistance arteries that need longer periods of dissection. To 
try to compensate for these problems, we have evaluated basal expression of the 
intracellular signaling pathways involved in H2O2 responses in mesenteric resistance 
arteries from normotensive and hypertensive rats. As can be observed in new Figures 1-
3, c-Src, ERK1/2 and RhoKinase expression were increased in mesenteric arteries from 
SHR compared to WKY which might help to explain, at least in part, the increased 
participation of these intracellular pathways in H2O2 and/or TXA2-induced responses in 
SHR vessels.  
 
2. Page 8, 1st para: It is somewhat surprising that ROCK inhibition did not affect 
phenylephrine (PE)-induced vasoconstriction in WKY or SHR vessels while it did affect 
contraction in response to H2O2 and U46619 at least in SHR. Please document that 
wall tension in response to PE was the same and stable over the experimentation time 
with and without ROCK inhibition.  
 
 
We understand Reviewer´s concerns about the effect of Y27632. As shown in the Table 
below, there seems to be a tendency to need a slightly higher dose of Phe to achieve 
approximately 50% of KCl responses, although this difference is not significant. 
Similarly, Phe responses seem to be slightly smaller in Y277632 incubated arteries that 
in control vessels, but again did not achieve statistical differences. Therefore, we 
believe that the effects of Y277632 on H2O2 or U46619-induced contractile responses 
are specifically due to the role of Rho Kinase in the effects of these compounds and 
only in SHR arteries. 
 
SHR
Rat Exp. Condition Dose Phe* (uM) Response (% KCl) Exp. Condition Dose Phe* (uM) Response (% KCl) 
SHR1 control 1,00 36,53 y27632 3 23,32
SHR2 control 2,00 20,99 y27632 2 81,39
SHR3 control 2,00 54,46 y27632 2 38,05
SHR4 control 2,00 81,55 y27632 2 43,73
SHR5 control 2,00 60,34 y27632 3 17,78
SHR6 control 2,00 64,61
SHR7 control 3,00 19,76
Mean 2,00 48,32 2,40 40,85
SEM 0,2 8,8 0,2 11,2
t-test vs control t-test vs control
0,254981145 0,606586138
Dose Phe* indicates Phe needed to achieve a contractile response of aprox 50% of KCl response.  
 
 
3. NADPH oxidase assay: Why was H2O2 added in cumulative doses? Did you 
obtain a full concentration response curve for NADPH-dependent superoxide 
formation? What was the H2O2 concentration for the data presented in Fig. 4? 
 
We apologize for the lack of clarity. We did not obtain a full concentration response 
curve for NADPH-dependent superoxide formation. The reason of adding H2O2 in 
cumulative doses was just to add H2O2 in the same way that was added to the organ bath 
for the contractile contraction response curves. Therefore, the final concentration of 
H2O2 in the samples was 100 µM. This aspect has been now clarified in the methods 
section (page 9, first paragraph).   
 
4. Although previous data of the authors showed low rates of superoxide formation 
in WKY-vessels and no effect of antioxidants on H2O2-induced vasoconstriction, it 
should be confirmed that H2O2 does not activate NADPH oxidase activity in WKY 
vessels. 
 
Following Reviewer´s suggestion we have performed new experiments to evaluate 
NADPH oxidase activity in WKY vessels in response to H2O2. Interestingly, in MRA 
from WKY rats, H2O2 also activated NAD(P)H Oxidase. These results are now shown 
in the manuscript (Page 14, second paragraph). This and our previously published 
results (García-Redondo et al., J Pharmacol Exp Ther. 2009;328:19-27; García-Redondo et al., J 
Hypertens. 2009;27:1814-22) suggest that although H2O2 activates NAD(P)H Oxidase in 
 
arteries from normotensive animals, this does not have a role in H2O2-induced 
contraction.  
 
 5.        Page 11, 1st paragraph: The authors compare data obtained with SQ29548, 
PD98059 and the combination of the two. The data were obviously obtained in separate 
experiments (Fig. 1 SQ29548 alone, the other two in Fig. 2) with quantitatively different 
responses in the control groups. How were between experiment comparisons performed 
(statistics)? 
 
The Reviewer is right. For all the figures, the different experimental conditions were 
performed in parallel in separate segments. Thus, for each inhibitor to be tested, control 
and drug-incubated segments from the same animal were used. This is the reason 
explaining why the controls are slightly different from one figure to the other. For 
Figure 2, our experimental set up was also the same. Thus, in the same experiment (rat) 
we had Control, PD98059-, SQ29548- and PD98059+SQ29548-incubated segments. In 
the previous version of the manuscript, we had omitted the SQ29548 data to avoid 
redundancy with data in Figure 1. We have now added the respective data of SQ29548-
incubated arteries in Figure 2.  
 
Page 11, 2nd paragraph: The authors report that the responses to Y27632 and 
Y27632+SQ29548 were not different (results section and abstract). However, at the 
highest H2O2 concentration the contraction is about 20-30% less in the combined 
group than in the Y27632 only group (SHR vessels). The control group shown in Fig. 3 
appears to be the same as in Fig 1. 
 
Although there seems to be less contraction in the combined group, neither one-way 
ANOVA nor individual Bonferroni t-test at this dose give statistical significance.  
Yes, the control group in Figure 3 is the same as in Figure 1 because from each animal 
we were able to test different inhibitors (we can mount up to 12 different arteries from 
one animal) and therefore the control would be the same for both inhibitors. The fact 
that in other Figures the controls are different is because not all protocols could be 
tested in the same animals and different animals were used thereafter. As mentioned 
above, in each animal there was always the control situation.  
 
 The concentration response curves for U46619 (controls, filled squares) appear to be 
the same in Figs. 1-3 although the numbers of individuals vary (SHR panels). Please 
explain how the study was organized to allow for proper comparison and analysis for 
effects of rat strain and treatment (statistics). 
 
The Reviewer is right. The same concentration curve for U46619 is displayed in Figures 
1-3 and all the inhibitors were evaluated in the same animals therefore having the same 
controls. We apologize for the number of animals in Figure 3. This was a mistake. The 
correct number is 6 for both figures. This has been now corrected in the new version of 
the manuscript.  
 
 Minor 
 
 Page 7: Please indicate the phenylephrine concentration used for precontraction. 
 
 
The concentration of Phenylephrine used for precontraction was that to achieve 
approximately 50% of maximal response. This has been now added in the revised 
version of the manuscript (Page 8, line 1).  
 
 Page 10, line 6 from bottom: PPI reduced (not normalized)? the H2O2-induced TXA2 
release. 
 
We thank the Reviewer to point out this aspect. However, we believe that the term 
normalized is correct since as can be observed in Figure 1 PP1 incubation decreased 
TXB2 levels to reach those observed in control situation both in WKY and in SHR.  
 
 Answers to Reviewer 3 
We would like to thank the Reviewer for his/her constructive comments. The 
manuscript has undergone changes to include data from new experiments. All concerns 
raised have been addressed and a detailed list of changes made is attached. We believe 
that the paper is significantly improved and hope that it is now acceptable for 
publication. 
 
 Major concerns 
 
 1. Although the study is well-conducted and the key findings of the present study as well 
as differences between the vascular responses in SHR and WKY are clear and nicely 
demonstrated, the study somehow suffers just from being an extension of their previous 
study and the data are to some extent confirmatory. In their previous studies the authors 
have already demonstrated the strain-related difference in H2O2-induced contractile 
responses, and on the other hand, the involvement of c-Src, ERK1/2 and Rho kinases in 
the pathogenesis of vascular dysfunction with hypertension has already been 
demonstrated in several previous studies. Therefore the novelty of the present study 
remains unfortunately rather limited. 
 
We understand Reviewer´s concerns. It is true that in our previous studies we have 
demonstrated that H2O2 contraction and basal and H2O2 -stimulated TXA2 production 
were greater in SHR mesenteric arteries compared to WKY (García-Redondo et al., J 
Pharmacol Exp Ther. 2009;328:19-27; García-Redondo et al., J Hypertens. 2009;27:1814-22). It is 
important to emphasize that we needed to repeat these experimental protocols in order 
to deeply analyze the underlying intracellular mechanisms responsible of H2O2 actions 
and this was no evaluated in any of our previous studies. It is also true that many papers 
have demonstrated the key role of c-Src, ERK1/2 and Rho kinase in vascular 
dysfunction in hypertension. However, to our knowledge very few papers have 
demonstrated specifically the intracellular pathways responsible of H2O2 responses in 
hypertension in whole arteries. In this sense, it is important to note that most of the 
articles evaluating intracellular pathways in hypertensive vascular responses have been 
performed in isolated cultured vascular cells or in response to other stimuli such as 
Angiotensin II.   
Following Reviewer´s suggestion we have performed new experiments in order to 
enhance the novelty of the manuscript. We have therefore focused our efforts in 
evaluating the role of mitochondrial oxidative stress in some of the observed effects. 
This is an important aspect since recent studies demonstrate the key role of H2O2 and 
mitochondria in vascular dysfunction in Ang II-induced hypertension (for review see 
Dikalov and Ungvari Z. Am J Physiol Heart Circ Physiol. 2013;305:H1417-27), although to our 
knowledge no studies on this regard have been performed in a model of essential 
hypertension such as the SHR. Herein we demonstrate for the first time, that prostanoids 
particularly TXA2, are able to activate the relationship existing between NADPH 
oxidase and mitochondria in hypertension, that this has a role in vascular dysfunction 
induced by H2O2 and that c-Src has a key role in these effects. These aspects have been 
properly discussed throughout the manuscript.  
   
 
 2. The authors should consider analyzing the expression (total and phosphorylated 
forms by Western blot) of their target proteins, and if possible vascular superoxide 
production. 
 
We agree with the Reviewers 3 and 2 that studies on differential activation of the 
intracellular pathways involved in H2O2 responses would have added more convincing 
evidences. We have tried to perform these experiments by evaluating the effect of H2O2 
on ERK1/2 and c-Src activation in mesenteric resistance arteries. Unfortunately, we 
have observed that basal protein activation was very high and we were not able to see 
further activation in response to H2O2. We believe that this might be due to the fact that 
dissection of the mesenteric resistance arteries takes longer than dissection of other 
vessels such as aorta and therefore, it is possible that spontaneous kinase activation 
might be occurring. Most of the articles evaluating intracellular pathways in response to 
different stimuli usually study effects on isolated cell cultured systems (i.e smooth 
muscle cells or endothelial cells) in which the stimulation conditions are well 
controlled. In fact, in a previous article Tabet et al., (J Hypertens. 2005 23(11):2005-12) 
demonstrated that H2O2 stimulated phosphorylation of ERK1/2 in cultured vascular 
smooth muscle cells being this activation greater in SHR than in WKY. We cannot also 
forget that these intracellular signaling pathways are usually activated within few 
minutes of stimulation. Therefore, it is not surprising that kinase activation studies are 
more difficult to perform in whole arteries such as mesenteric resistance arteries that 
need longer periods of dissection. To try to compensate for these problems, we have 
evaluated basal expression of the intracellular signaling pathways involved in H2O2 
responses in mesenteric resistance arteries from normotensive and hypertensive rats. As 
can be observed in new Figures 1-3, c-Src, ERK1/2 and RhoKinase expression were 
increased in mesenteric arteries from SHR compared to WKY which might help to 
explain, at least in part, the increased participation of these intracellular pathways in 
H2O2 and/or TXA2-induced responses in SHR vessels.  
As suggested by the Reviewer, we have also determined vascular O2
.-
 production in 
SHR mesenteric vessels. As shown in new Figure 4, H2O2 increased O2
.-
 production that 
was abolished by furegrelate, U0126 and PPI. This would be in agreement with the 
effects of these inhibitors on NADPH Oxidase activity.  
 
This article examines the signaling pathways involved in H2O2 vascular responses in 
hypertension. Our results demonstrate increased vasoconstrictor responses to H2O2 and 
the TP analogue U46619 and increased TXA2 production in arteries from hypertensive 
(SHR) than normotensive (WKY) rats. In arteries from WKY, c-Src mediates H2O2 
contractile responses by modulating TXA2 release and TXA2 effect. In SHR, H2O2 
contraction is mediated by c-Src-dependent TXA2 release which further activates Rho 
Kinase, c-Src and the relationship between mitochondria and NAD(P)H Oxidase. 
Moreover, ERK1/2 activation contributes to H2O2 contraction in SHR through effects 
on mitochondria/NAD(P)H Oxidase.  
 
Condensed abstract
List of non-standard abbreviations: ROS: reactive oxygen species; H2O2: hydrogen 
peroxide; MAPKs: mitogen activated protein kinases; O2
.-
: superoxide anion; TXA2: 
thromboxane A2; VSMC: vascular smooth muscle cells; MRA: mesenteric resistance 
arteries; SHR: spontaneously hypertensive rats; WKY: Wistar Kyoto; KHS: Krebs 
Henseleit solution. 
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Abstract 
Aim: to analyze the signaling pathways involved in H2O2 vascular responses in 
hypertension. Methods: Vascular function, thromboxane A2 (TXA2) production, 
oxidative stress and protein expression were determined in mesenteric resistance arteries 
(MRA) from hypertensive (SHR) and normotensive WKY rats. Results: H2O2 and the 
TP agonist U46619 induced greater contractile responses in MRA from SHR than 
WKY. Moreover H2O2 increased TXA2 production more in SHR than in WKY. The c-
Src inhibitor PP1 reduced H2O2- and U46619-induced contraction and TXA2 release in 
both strains. The ERK1/2 inhibitor PD98059 reduced H2O2 but not U46619-induced 
contraction only in SHR arteries. The Rho Kinase inhibitor Y26372 reduced H2O2 and 
U46619-induced contractions only in SHR arteries. Basal c-Src, ERK1/2 and Rho 
Kinase expression were greater in MRA from SHR than WKY. In SHR, the 
combination of PD98059 with the TP antagonist SQ29548 but not with Y27632, 
inhibited the H2O2 contraction more than each inhibitor alone. H2O2 and U46619 
increased NAD(P)H Oxidase activity and O2
.-
 production and decreased mitochondrial 
membrane potential in vessels from SHR. The effects induced by H2O2 were abolished 
by inhibitors of TXA2 synthase, ERK1/2 and c-Src. The mitochondrial antioxidant 
mitoTEMPO reduced H2O2-induced contraction and NAD(P)H Oxidase activation. 
Conclusions: In arteries from WKY, c-Src mediates H2O2 contractile responses by 
modulating TXA2 release and TXA2 effect. In SHR, H2O2 contraction is mediated by c-
Src-dependent TXA2 release which further activates Rho Kinase, c-Src and the 
relationship between mitochondria and NAD(P)H Oxidase. Moreover, ERK1/2 
activation contributes to H2O2 contraction in SHR through effects on 
mitochondria/NAD(P)H Oxidase.  
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Keywords: c-Src, ERK1/2, Rho Kinase, NAD(P)H Oxidase, mitochondria, H2O2, SHR, 
mesenteric resistance arteries 
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Introduction 
Hydrogen peroxide (H2O2) is a cell-permeant and highly stable reactive oxygen specie 
(ROS) that is produced mainly by the dismutation of superoxide anion (O2
.-
) by 
superoxide dismutase and also directly by the NOX-4 isoform of the NAD(P)H Oxidase 
[1,2]. H2O2 levels are tightly regulated by intracellular and extracellular enzymes 
including catalase, glutathione peroxidase, thioredoxin, and other peroxyredoxins, 
which convert H2O2 to water and O2 [1,3]. It is now accepted that the vascular 
functional effects of H2O2 are very complex and depend among other factors, of the 
specific vascular bed studied and the nature of the pre-contractile agent. Thus, H2O2 can 
either contract or relax arteries from different species in resting state or after 
preconstriction with stimuli like phenylephrine, high K
+
 solution or others [1,4-7].  
The relationship between hypertension and the increased production of ROS has been 
extensively demonstrated in experimental models of hypertension and in humans [3]. 
Thus, increased levels of H2O2 have been described in plasma [8] and tissues [9] from 
hypertensive patients. More importantly, H2O2 induces greater contractile responses in 
conductance and resistance vessels from hypertensive than normotensive animals 
[4,6,7,10,11] further promoting vascular dysfunction. Two of the major ROS sources at 
vascular level include NAD(P)H Oxidase and mitochondria [2, 12]. Interestingly, in the 
past few years a cross talk between mitochondria and NAD(P)H oxidase has been 
demonstrated in the setting of hypertension with H2O2 having a pivotal role [12]. This 
relationship is particularly evident for Angiotensin II stimulation and seems to have a 
role in vascular function alterations [12-15]. However, whether this is also present in 
essential hypertension is less known.  
Among the mechanisms whereby H2O2 induces vasoconstriction, stimulation of 
cyclooxygenase and release of the vasoconstrictor TXA2 appear to be pivotal [4-6,16]. 
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Several studies have demonstrated the role of c-Src, ERK1/2 mitogen activated protein 
kinases (MAPKs) and Rho Kinase in the contractile effects of H2O2 or the TXA2 
analogue U46619 in different vessels from mice or rat [17-22]. In addition, in cultured 
vascular smooth muscle cells (VSMC) the activation of ERK1/2 induced by H2O2 is 
greater in spontaneously hypertensive (SHR) than in normotensive Wistar Kyoto rats 
(WKY) [23]. However, the specific intracellular pathways involved in H2O2-induced 
TXA2 release or whether these intracellular pathways activated by H2O2 and/or TXA2 
are different in vessels from hypertensive animals and participate in vascular function, 
is unknown.  
We have previously demonstrated that H2O2 induces greater TXA2 release and 
contractile responses in mesenteric resistance arteries (MRA) from SHR than WKY 
[6,7]. In addition, in SHR arteries, the contractile effect of H2O2-derived TXA2 is 
partially mediated by O2
.-
 production [6,7]. In the present study we aimed to analyze the 
intracellular signalling pathways involved in the effects of H2O2 in arteries from WKY 
and SHR and the role of NAD(P)H Oxidase and mitochondrial oxidative stress in these 
effects.  
Methods 
Animals 
6 month-old male SHR and WKY rats were obtained from colonies maintained at the 
Animal Quarters of the Facultad de Medicina of the Universidad Autónoma de Madrid. 
The investigation conforms to the Guide for the Care and Use of Laboratory animals 
published by the US National Institutes of Health (NIH Publication No. 85-23, revised 
1996) and with the current Spanish and European laws (RD 223/88 MAPA and 609/86). 
Rats were euthanized by decapitation and the mesenteric vascular bed and the aorta 
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were removed and placed in cold (4°C) Krebs–Henseleit solution (KHS) (in mmol/L: 
115 NaCl, 25 NaHCO3, 4.7 KCl, 1.2 MgSO4.7H2O, 2.5 CaCl2, 1.2 KH2PO4, 11.1 
glucose and 0.01 Na2EDTA) bubbled with a 95% O2–5% CO2 mixture. Segments of 
second and third order branches of the superior mesenteric artery and aorta were 
dissected free of fat and connective tissue. 
Reactivity experiments 
Third order branches of the mesenteric artery, 2 mm in length, were mounted in a small 
vessel dual chamber myograph for measurement of isometric tension. Two steel wires 
(40 μm diameter) were introduced through the lumen of the segments and mounted 
according to the method described by Mulvany and Halpern [24]. After a 30 min 
equilibration period in oxygenated KHS at 37 °C and pH = 7.4, segments were stretched 
to their optimal lumen diameter for active tension development. This was determined 
based on the internal circumference-wall tension ratio of the segments by setting their 
internal circumference, Lo, to 90% of what the vessels would have if they were exposed 
to a passive tension equivalent to that produced by a transmural pressure of 100 mmHg 
[20 24]. Segments were washed with KHS and left to equilibrate for 30 min; segment 
contractility was then tested by an initial exposure to a high K
+
 solution (120 mmol/L 
K
+
-KHS, which was identical to KHS except that NaCl was replaced by KCl on an 
equimolar basis). The maximum response to K
+
-KHS was similar in arteries from both 
strains (WKY: 2.8 ± 0.2 mN/mm, n=12 SHR: 2.9± 0.3 mN/mm, n=15). The presence of 
endothelium was determined by the ability of 10 µmol/L acetylcholine to induce 
relaxation in arteries precontracted with phenylephrine to achieve a contractile response 
of approximately 50% of maximum response.  
In previous experiments, we observed that H2O2 does not induce vascular responses in 
quiescent mesenteric arteries. We therefore performed the experiments in 
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phenylephrine-contracted vessels at a dose that produced ~ 50% K+-KHS contraction, 
as described [6]. Once the presence of endothelium was determined, a cumulative 
concentration-response curve to H2O2 (1-100 μmol/L) or U46619 (0.1 nmol/L-1 
μmol/L) was performed in segments contracted with phenylephrine as described above. 
The participation of different signalling pathways was analysed by preincubation of the 
arteries with PD98059, an ERK1/2 MAPK inhibitor, Y27632, a Rho Kinase inhibitor, 
PP1, a c-Src inhibitor or mito-TEMPO, a mitochondrial targeted superoxide dismutase 
mimetic. In another set of experiments, arteries were incubated with the TP antagonist 
SQ29548 alone or in combination with PD98059 or with Y27632. All drugs were added 
30 min before the H2O2 or U46619 concentration-response curve and none of the 
inhibitors modified phenylephrine vasoconstriction. At the end of the experiment, the 
viability of the vessels was tested by re-exposure to K
+
-KHS. 
Measurement of TXA2 production 
Second and third order branches of the mesenteric artery from WKY and SHR were 
incubated in oxygenated KHS (37ºC). After 30 min stabilization, phenylephrine (1 
µmol/L) was added for 4 min. Thereafter, cumulative doses of H2O2 (1-100 µmol/L, 4 
min each dose) were added to the incubation medium to mimic the same conditions to 
those found in the organ bath. The participation of c-Src on TXA2 release was evaluated 
by preincubation of the arteries with PP1 30 min before phenylephrine. At the end, the 
medium was collected and frozen (-80ºC) for further analysis. The levels of the 
metabolite of TXA2, TXB2, were determined using a commercial enzyme immunoassay 
kit (Cayman Chemical, Ann Harbor, Mi, USA). The levels of TXB2 were normalized 
per µg of protein.  
NAD(P)H Oxidase activity 
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The lucigenin-enhanced chemiluminescence assay was used to determine the NAD(P)H 
Oxidase activity in mesenteric homogenates. Second and third order branches of the 
mesenteric artery from SHR and WKY were incubated in oxygenated KHS (37ºC). 
After 30 min stabilization, phenylephrine (1 µmol/L) was added for 4 min. Thereafter, 
cumulative doses of H2O2 were added to the incubation medium to mimic the same 
experimental conditions that those found in the organ bath. Final concentration of H2O2 
was 100 µmol/L. In SHR vessels the participation of TXA2 synthase, ERK1/2, Rho 
Kinase and c-Src on NAD(P)H Oxidase activity was evaluated by preincubation with 
the respective inhibitors furegrelate, U0126 (another ERK1/2 MAPK inhibitor), Y27632 
and PP1, that were added 30 min before phenylephrine. In another set of experiments, 
aortic segments were incubated with U46619 (10 µmol/L) in the absence or in the 
presence of PP1, or with H2O2 in the absence or in the presence of mito-TEMPO or the 
inhibitor of the complex I of the electron transport chain, rotenone. At the end, tissues 
were homogenized in lysis buffer (in mmol/L: KH2PO4, 50; ethyleneglycoltetraacetic 
acid, 1; sucrose 150; pH=7.4). The reaction was started by the addition of NAD(P)H 
(0.1 mmol/L) to the suspension containing sample, lucigenin (5 µmol/L) and assay 
phosphate buffer. The luminescence was measured in a plate luminometer (AutoLumat 
LB 953, Berthold, Germany). Buffer blank was subtracted from each reading. Activity 
is expressed as relative light units/mg protein and variations of NAD(P)H Oxidase 
activity were calculated as percentage of control situation.  
In situ detection of vascular O2
.-
 production 
The oxidative fluorescent dye dihydroethidium (DHE) was used to evaluate O2
.-
 
production in situ, as previously described [7]. Third order branches of the mesenteric 
artery from SHR were incubated in oxygenated KHS (37ºC). After 30 min stabilization, 
arteries were stimulated with H2O2 in the absence or in the presence of furegrelate, 
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U0126 or PP1, as described above. Then arterial segments were placed in PBS 
containing 30% sucrose for 20 min, transferred to a cryomold containing Tissue Tek 
OCT-embedding medium, and frozen in liquid nitrogen. Serial sections were 
equilibrated under identical conditions for 30 min at 37°C in Krebs-HEPES buffer (in 
mmol/l: 130 NaCl, 5.6 KCl, 2 CaCl2, 0.24 MgCl2, 8.3 HEPES, 11 glucose, pH=7.4). 
Fresh buffer containing DHE (2 µmol/l) was topically applied onto each tissue section, 
cover-slipped, incubated for 30 min in a light-protected humidified chamber at 37°C 
and then viewed with a fluorescent laser scanning confocal microscope (Leica TCS SP2 
equipped with a krypton/argon laser, x40 objective). Every day, control and H2O2-
incubated arteries in the absence or in the presence of the different inhibitors were 
imaged in parallel using the same imaging settings. Fluorescence was detected with a 
568 nm long-pass filter. For quantification, two-three rings per animal were sampled for 
each experimental condition and averaged. The mean fluorescence densities in the target 
region were calculated. To minimize laser fluctuations from one day to another, data 
were expressed as % of signal in control arteries.  
Mitochondrial Membrane Potential (ΔΨ) 
Mitochondrial membrane potential was monitored with the fluorescent probe 
tetramethylrhodamine methyl ester (TMRE, Ex/Em, 543/573 nm) (Life Technologies). 
Second and third order branches of the mesenteric artery or aortic segments from SHR 
were incubated in oxygenated Krebs-HEPES buffer (37ºC). After 30 min stabilization, 
arteries were stimulated with H2O2 or with U 46619 in the absence or in the presence of 
furegrelate, U0126 or PP1 as described above. Thereafter, arteries were incubated with 
Krebs-HEPES buffer containing TMRE (0.1 µmol/L) 20 min, 37ºC. After washing, 
fluorescence intensity was measured with a spectrofluorimeter (FLUOstar OPTIMA 
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BMG Labtech). Fluorescence intensity values were normalized by the amount of 
proteins and values were expressed as a % of control arteries.  
Western blot analysis  
MRA from WKY and SHR rats were dissected free of fat and connective tissue and 
frozen at -80ºC. Protein expression was determined in homogenates as previously 
described [6]. Briefly, proteins (30 μg) were separated by SDS-PAGE and then 
transferred to polyvinyl difluoride membranes overnight. Membranes were incubated 
overnight with rabbit or mouse primary antibodies for Rho kinase (1:1000 Santa Cruz 
Biotechnology, Santa Cruz, California, USA), c-Src (1:1000 Santa Cruz 
Biotechnology), p-Tyr
418
-c-Src (1:1000 Biosource International, Inc USA), p-ERK1/2 
(1:1000) and GADPH (1: 5000 Sigma Chemical, Co., St Louis, Mi, USA). After 
washing, membranes were incubated with anti-rabbit or anti-mouse IgG secondary 
antibodies conjugated to horseradish peroxidase (1:5000, Bio-Rad, Laboratories, 
Hercules, CA, USA). The immunocomplexes were detected using an enhanced 
horseradish peroxidase-luminol chemiluminiscence system (ECL Plus, Amersham 
International; Little Chalfont, UK) and subjected to autoradiography (Hyperfilm ECL, 
Amersham International). Signals on the immunoblot were quantified using the 
Quantity One version 4.6.9 computer program. 
Drugs and solutions 
H2O2, acetylcholine, furegrelate, phenylephrine, 9, 11-di-deoxy-11 9-epoxymethano 
prostaglandin F2 (U46619) and rotenone, were obtained from Sigma Chemical Co. 
SQ29548 was obtained from ICN Iberica, (Barcelona, Spain). PP1, Y27632 and 
PD98059 were obtained from Biomol (Plymouth Meeting, PA, USA). U0126 was 
obtained from Calbiochem (San Diego, CA). mito-TEMPO was obtained from Santa 
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Cruz Biotechnology Inc. U46619 was dissolved in ethanol, PP1 and PD98059 were 
dissolved in DMSO. Further dilutions were in distilled water. 
Data analysis and statistics 
Contractile responses for each dose are expressed as a percentage of contraction to K
+
-
KHS. All data are expressed as mean values ± standard error of the mean (SEM). 
Results were analyzed by Student’s t-test, one-way or two-way ANOVA using 
GraphPad Prism Software (San Diego, CA, USA). A P value below 0.05 was 
considered significant. 
Results 
As previously described [6], H2O2-induced contraction (1-100 μmol/L) was greater in 
MRA from SHR than WKY rats (Maximum response: WKY: 8.4±2.5, n=9; SHR: 
39.1±6.8 %, n=10; p<0.01). In addition, U-46619-induced contraction (0.1 nM-1 μM) 
was also greater in arteries from SHR than WKY (Maximum response: WKY: 57.9±3.5, 
n=7; SHR: 69.4±3.2 %, n=6; p<0.05). 
Role of c-Src in H2O2 contraction 
Previous studies have demonstrated a role of c-Src in mediating H2O2-induced 
contraction in normotensive animals [19]. The c-Src inhibitor PPI (1 µmol/L) abolished 
the H2O2-induced contractile response in MRA from WKY and reduced H2O2 responses 
in SHR (Figure 1A). As previously described [6] the TP antagonist, SQ29548 (1 
µmol/L) also abolished H2O2-contractile response in MRA from WKY and reduced it in 
SHR (Figure 1A). PP1 also decreased U46619-induced contractile responses both in 
WKY and SHR mesenteric arteries (Figure 1B). In agreement with our previous report 
[6], basal TXA2 was greater in SHR than WKY and H2O2 induced TXA2 release in both 
strains reaching higher levels in SHR compared to WKY (Figure 1C). PPI normalized 
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the H2O2-induced TXA2 release of mesenteric arteries from WKY and SHR (Figure 
1C). Additionally, increased basal activation of c-Src was observed in MRA from SHR 
compared to WKY (Figure 1D). All together, our results demonstrate that in MRA from 
WKY and SHR, c-Src mediates H2O2-induced TXA2 release and TXA2 contractile 
effects. However, additional mechanisms might be involved in H2O2 contractile 
responses in SHR.  
Role of ERK1/2 in H2O2 contraction 
Another important intracellular pathway activated by H2O2 is ERK1/2 MAPK 
[18,19,22,23]. Then, we evaluated the involvement of this kinase in H2O2 contraction by 
using the specific inhibitor PD98059 (10 µmol/L). As shown in Figure 2A, PD98059 
inhibited H2O2-induced contraction in MRAs from SHR but not from WKY. In 
addition, PD98059 did not affect U46619-induced contractile responses neither in WKY 
nor in SHR (Figure 2B). The combination of SQ29548 and PD98059 in arteries from 
SHR induced a greater inhibitory effect of H2O2 contraction than PD98059 and 
SQ29548 alone (Figure 2A) and almost abolished H2O2-induced contraction. In 
addition, basal ERK1/2 activation was greater in MRA from SHR than WKY (Figure 
2C). These results suggest that activation of ERK1/2 by H2O2 independent of TP 
activation might be also responsible of the vascular contraction in SHR.  
Role of Rho Kinase in H2O2 contraction 
It has been suggested that excessive activation of the RhoA/Rho-Kinase pathway might 
participate in the alteration of the vasoconstrictor responses observed in cardiovascular 
diseases including hypertension [25]. As shown in Figure 3A, the inhibitor of Rho 
Kinase Y27632 (1 µmol/L) inhibited H2O2-induced contraction in SHR arteries but not 
in WKY. Similarly, Y27632 inhibited U46619-induced contraction in SHR but not in 
WKY (Figure 3B). We then combined SQ29548 and Y27632 in arteries from SHR. The 
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combination of both drugs induced similar effects to that produced by Y27632 (Figure 
3A) or SQ29548 (P>0.05) alone. In addition, Rho kinase expression was greater in 
MRA from SHR than WKY (Figure 3C). This suggests that the participation of Rho 
Kinase in H2O2 effect in SHR might be mediated via TXA2.  
H2O2 induces NAD(P)H Oxidase activation. Mechanisms involved 
We have previously described that H2O2-induced vasoconstriction in MRA from SHR 
but not from WKY is dependent of TXA2-derived O2
.-
 production [6,7]. Herein we 
aimed to determine whether H2O2 might activate NAD(P)H Oxidase activity in SHR 
and the possible mechanisms involved. As shown in Figure 4A, H2O2 induces 
NAD(P)H Oxidase activation in MRA from SHR. This activation was inhibited by the 
TXA synthase inhibitor furegrelate (1 µmol/L), by PP1, by the ERK1/2 inhibitor, 
UO126 (10 µmol/L), but not by the Rho Kinase inhibitor Y27632. Accordingly, O2
.-
 
was
 
produced in MRA from SHR in response to H2O2, and this production was reduced 
by furegrelate, PP1, or UO126 (Figure 4B). In addition, in aorta from SHR U46619 
increased NAD(P) Oxidase activity and this increase was prevented by PP1. 
Interestingly, in MRA from WKY rats, H2O2 also activates NAD(P)H Oxidase (% 
Control:  154 ± 5.6 n=6). All together, these results suggest that TXA2 plays a central 
role in the activation of NAD(P)H Oxidase by H2O2 in SHR. In addition, this activation 
is tightly regulated by c-Src and ERK1/2. 
A cross talk between mitochondria and NAD(P)H oxidase has been demonstrated in 
hypertension with H2O2 having a pivotal role [12]. We therefore aimed to evaluate the 
role of mitochondrial oxidative stress in H2O2 effects. As shown in Figure 5A, the 
mitochondrial targeted superoxide dismutase mimetic mito-TEMPO (0.5 µmol/L), 
inhibited H2O2-induced contraction in SHR arteries. Moreover, both mito-TEMPO and 
the inhibitor of mitochondrial respiratory chain rotenone (5 µmol/L), abolished the 
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H2O2-induced NAD(P)H Oxidase activation in aorta from SHR (Figure 5B). 
Mitochondrial membrane potential (ΔΨ) is essential for normal mitochondrial function. 
Treatment of MRA with H2O2 caused partial depolarization of mitochondria (Figure 
5C) and this effect was blunted by furegrelate, U0126 or PP1. H2O2 effect on membrane 
potential was mimicked in aorta from SHR by U46619 (Figure 5D). The decrease in 
membrane potential induced by U46619 was prevented by pretreatment with PP1 
(Figure 5D). These results suggest that H2O2-derived TXA2 induces mitochondrial 
dysfunction that participates in H2O2 vascular effects in hypertension.  
Discussion 
The results of the present study demonstrate that different intracellular signalling 
pathways are responsible of H2O2 contraction in MRA from SHR and WKY. In arteries 
from WKY, c-Src mediates H2O2 contractile responses by modulating TXA2 release and 
TXA2 effect. In SHR, H2O2 contraction is mediated by c-Src-dependent TXA2 release 
which further activates Rho Kinase, c-Src and the relationship between mitochondria 
and NAD(P)H Oxidase. Moreover, TXA2-independent activation of ERK1/2 contributes 
to H2O2 contraction in SHR through effects on mitochondria/NAD(P)H Oxidase (Figure 
6). All together, these mediators would explain the increased contractile response 
induced by H2O2 in hypertension.  
Role of c-Src 
The Src family of nonreceptor tyrosine kinases is considered prime targets for redox 
regulation [21]. The Src family has been implicated in signal transduction of constrictor 
responses to different stimuli including Angiotensin II and prostanoids like PGF2α, 
which appear to be mediated at least in part, via ROS [21]. In addition, c-Src is 
activated by exogenous H2O2 in various cell types including VSMC and endothelial 
cells [23, 26-28], it mediates H2O2 contractile responses [19] but not U46619 
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contractile responses [19] in aorta from normotensive animals and it is more activated 
in cultured VSMC from SHR compared to WKY [29]. Herein we demonstrate that c-
Src mediates H2O2 contractile responses in MRA from normotensive and hypertensive 
rats. The increased basal activation of this kinase observed in vessels from SHR might 
contribute to the increased H2O2 vasoconstrictor responses observed in SHR compared 
to WKY. The effects of c-Src on vascular contraction seem to be explained not only by 
inhibition of TP activation, as demonstrated by the inhibition of U46619-induced 
contractile responses by PP1, but also by the inhibition of H2O2-induced TXA2 
production and suggest that c-Src is an early mediator of H2O2 effects.  
We previously demonstrated that H2O2 contractile responses in SHR-but not in WKY- 
are dependent on O2
.-
 derived presumably from NAD(P)H Oxidase activated by TXA2 
[6,7]. Herein, we extend these observations and demonstrated that the activation of 
NAD(P)H Oxidase activity and O2
.-
 production induced by H2O2 in mesenteric arteries 
from SHR were dependent on TXA2 and c-Src. Accordingly, TP activation increased 
NAD(P)H Oxidase activity in a c-Src dependent manner in vessels from hypertensive 
rats. Other studies have demonstrated that c-Src regulates vascular NAD(P)H Oxidase-
derived O2
.-
 generation after Angiotensin II [30,31], endothelin-1 [32] or H2O2 [30,33]. 
Role of ERK1/2  
Other candidates to modulate H2O2 and TXA2-induced contractile responses might be 
components of the MAPK family. ERK1/2 participates in the H2O2 contractile response 
in different vessels from normotensive animals [19,22]. In addition, Tabet et al [23] 
described that H2O2 induced ERK1/2 activation in cultured VSMC from SHR and 
WKY. More importantly, this activation was greater in cells from hypertensive than 
normotensive animals [23]. Inhibition of ERK1/2 with PD98059 inhibited H2O2 
contractile responses only in SHR arteries. In addition, basal activation of ERK1/2 was 
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greater in MRA from to SHR than WKY. Interestingly, PD98059 did not modify 
U46619-induced contractions and the combination of SQ29548 plus PD98059 exerted 
greater inhibitory effects on H2O2 contraction than each inhibitor alone. These results 
suggest that ERK1/2 might participate in H2O2 contraction through TXA2/TP 
independent pathways. In agreement with our study, inhibition of MAPK with 
PD98059 did not modify U46619-induced contraction in rat MRA from normotensive 
animals [17], although conflicting reports have been demonstrated depending on the 
vessel type and specie [17,34]. Supporting the role of ERK1/2 as the additional 
mediator involved in the hyperreactivity to H2O2 in SHR, U0126, another ERK1/2 
inhibitor, blocked H2O2-induced NAD(P)H Oxidase activity and O2
.-
 production in 
SHR, suggesting that the participation of ERK1/2 on H2O2 contraction might be due to 
NAD(P)H Oxidase-derived O2
.-
. The role of ERK1/2 in NA(D)PH Oxidase activation 
has been described for other stimuli like Angiotensin II [30,35]. 
A novel aspect derived from this study is the role of c-Src, ERK1/2 and TXA2 in the 
relationship triggered by H2O2 between mitochondria and NAD(P)H Oxidase. This is an 
important aspect since it has been demonstrated that this relationship is key to explain 
hypertension and endothelial dysfunction induced by Angiotensin II [12,13]. Our data 
demonstrate that H2O2-induced TXA2 is an important mediator of the loss of 
mitochondrial membrane potential that could increase mitochondrial ROS production 
and further NAD(P)H Oxidase activation in SHR vessels. This is also supported by the 
fact that U46619 mimicked the effects of H2O2 on mitochondrial membrane potential 
and NAD(P)H Oxidase activation. Interestingly, the intracellular signalling pathways 
responsible of these effects are c-Src and ERK1/2 which as mentioned, are crucial to 
explain vascular effects of H2O2. More importantly, this has a role in vascular function 
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since H2O2 responses in SHR arteries were greatly diminished by selective mitoROS 
blockade.   
Role of Rho Kinase 
The RhoA protein activation by contractile agonists allows the stimulation of Rho 
Kinase which mainly promotes muscle contraction through phosphorylation of myosin 
light chain phosphatase, thus playing a key role in Ca
2+
 sensitization induced by 
agonists [36]. It is generally accepted that RhoA/Rho Kinase expression and/or 
activation is greater in the hypertensive vasculature and participates of hypertension 
development [20,37-39]. In agreement, we observed that Rho kinase expression was 
greater in MRA from SHR than WKY rats. Previous studies have demonstrated that 
ROS, particularly O2
.
, can activate Rho Kinase and mediate vascular contraction 
[40,41]. Moreover, Chandra et al. [42] recently described that H2O2 can induce Rho 
Kinase translocation in endothelial cells. We observed that Y27632 inhibited H2O2 and 
U46619-induced contractile responses only in arteries from SHR, suggesting a role of 
Rho Kinase in vascular contraction in hypertension. In addition, these results suggest 
that the role of Rho Kinase in H2O2-induced responses in SHR might be related with 
the activation of TP receptors. In support of this hypothesis, no further inhibition was 
observed when Y27632 and SQ29548 were combined. Participation of Rho Kinase in 
H2O2-contractile response has been described [19-22] although conflicting results have 
been described depending on the vascular beds or the precontractile agent used 
[18,19,37,43]. Rho Kinase inhibitors did not modify U46619 contractions in 
normotensive mesenteric arteries [34]. In addition, Rho Kinase was not activated by 
H2O2 in pulmonary arteries [41] and it was not involved in H2O2 induced sustained 
contractile response in the same vascular bed from normotensive animals [44]. 
Interestingly, Dennis et al., [20] demonstrated that H2O2 elicits a greater contraction in 
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carotid artery from SHR than WKY that is TP-dependent and mediated by Rho Kinase 
in both strains. Besides its effects of VSM contraction, Rho Kinase plays a crucial role 
on the development of cardiovascular diseases through ROS production, inflammation, 
and VSMC proliferation, among others [45]. Rho Kinase upregulates different subunits 
of the NAD(P)H Oxidase (nox1, nox4, gp91phox, and p22phox) and increases 
Angiotensin II-induced ROS production [46]. However, in our experimental conditions, 
Rho Kinase was not involved in the activation of NAD(P)H Oxidase activity elicited by 
H2O2 in MRAs from SHR. 
A final issue deserves further consideration. In addition of the different signaling 
pathways involved in H2O2 or TXA2 responses, we should not forget that H2O2 induces 
greater TXA2 production in SHR than in WKY. Therefore, it is highly possible that the 
hyperresponsiveness to exogenous H2O2 observed in the SHR mesenteric arteries might 
be also explained by the H2O2-derived TXA2 overproduction that acting via TP 
receptors elicits activation of RhoA/Rho Kinase and c-Src. 
Conclusions 
Our results demonstrate that activation of signaling pathways such as ERK1/2, c-Src 
and Rho Kinase are key to explain the increased vasoconstrictor responses induced by 
H2O2 in vessels from hypertensive animals by modulating not only TXA2 production 
and/or signaling but also the existing relationship between mitochondria and NADPH 
oxidase. 
Perspectives 
The contribution of ROS to vascular damage in hypertension might be explained not 
only by the increased ROS bioavailability observed systemically or locally in 
hypertensive patients [8], but also by the enhanced redox signaling developed in these 
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conditions [47]. Our data further build on this notion demonstrating that different 
intracellular pathways are involved in H2O2 vascular effects in normotensive and 
hypertensive animals. Moreover, we demonstrate that oxidative stress is an important 
perpetuator of key inflammatory pathways including prostanoids and mitochondrial 
oxidative stress which act in relationship to induce vascular dysfunction. Improving our 
knowledge of H2O2 signaling at vascular level particularly in pathological conditions, 
will help us to develop more specific or more directed strategies to regulate ROS 
effects to treat hypertensive vascular damage. 
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Figure legends 
Figure 1. Effect of SQ29548 (1 µmol/L) and PP1 (1 µmol/L) on the concentration–
response curves to H2O2 (A) and U46619 (B) in phenylephrine-contracted mesenteric 
resistance arteries from Wistar–Kyoto (WKY) and spontaneously hypertensive (SHR) 
rats. Results are expressed as a percentage of K
+
-KHS contraction. ***P<0.001 vs 
control. (C) Effect of H2O2 in the absence and in the presence of PP1 on thromboxane 
B2 production by mesenteric resistance arteries from WKY and SHR. *P<0.05 vs WKY, 
#P<0.05 vs Control, †P<0.05 vs H2O2. (D) Densitometric analysis and representative 
western blots for pTyr
418
c-Src and c-Src protein expression in mesenteric resistance 
arteries from WKY and SHR. *P<0.05 vs WKY. Number of animals is indicated in 
parenthesis. 
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Figure 2. Effect of PD98059 (10 µmol/L), SQ29548 (1 µmol/L) or PD98059 plus 
SQ29548 on the concentration–response curves to H2O2 (A) or U46619 (B) in 
phenylephrine-contracted mesenteric resistance arteries from Wistar Kyoto (WKY) and 
spontaneously hypertensive (SHR) rats. Results are expressed as a percentage of K
+
-
KHS contraction. *P<0.05, ***P<0.001 vs control; †P<0.05 vs PD98059 or SQ29548. 
(C) Densitometric analysis and representative western blots for pERK1/2 protein 
expression in mesenteric resistance arteries from WKY and SHR. GADPH was used as 
loading control. *P<0.05 vs WKY. Number of animals is indicated in parenthesis. 
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Figure 3. Effect of Y27632 (1 µmol/L) or Y27632 plus SQ29548 (1 µmol/L) on the 
concentration–response curves to H2O2 (A) or U46619 (B) in phenylephrine-contracted 
mesenteric resistance arteries from Wistar–Kyoto (WKY) and spontaneously 
hypertensive (SHR) rats. Results are expressed as a percentage of K
+
-KHS contraction. 
*P<0.05; **P<0.01 ***P<0.001 vs control. C) Densitometric analysis and 
representative western blot for Rho kinase protein expression in mesenteric resistance 
arteries from WKY and SHR. GADPH was used as loading control. *P<0.05 vs WKY. 
Number of animals is indicated in parenthesis. 
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Figure 4. A) Effect of H2O2 (100 µmol/L) in the absence or in the presence of 
furegrelate (1 µmol/L), U0126 (10 µmol/L), PP1 (1 µmol/L) or Y26732 (1 µmol/L) on 
NAD(P)H Oxidase activity in mesenteric resistance arteries from spontaneously 
hypertensive (SHR) rats. B) Representative fluorescence confocal photomicrographs 
and quantitative analysis of vascular superoxide anion production in mesenteric 
resistance arteries from SHR untreated and treated with H2O2 in the absence and the 
presence of furegrelate, U0126 or PP1. Image size 375x375 µm. Images were captured 
with a fluorescence confocal microscope (x40 oil immersion objective, zoom 1). C) 
Effect of U46619 (10 μmol/L) in the absence or in the presence of PP1, on NAD(P)H 
Oxidase activity in aorta from SHR. Data are expressed as a percentage of control 
arteries. **P<0.01; ***P<0.001 vs Control; #P<0.05; ##P<0.01 vs H2O2 or U46619. 
Number of animals is indicated in parenthesis. 
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Figure 5. A) Effect of mito-TEMPO (1 µmol/L) on the concentration–response curve to 
H2O2 in phenylephrine-contracted mesenteric resistance arteries from spontaneously 
hypertensive (SHR) rats. Results are expressed as a percentage of K
+
-KHS contraction. 
B) Effect of H2O2 (100 µmol/L) in the absence or in the presence of mito-TEMPO or 
rotenone (1 µmol/L), on NAD(P)H Oxidase activity in aorta from SHR rats. Data are 
expressed as a percentage of control arteries. C) Effect of H2O2, in the absence or in the 
presence of furegrelate (1 µmol/L), U0126 (10 µmol/L) or PP1 (1 µmol/L), on 
mitochondrial membrane potential in mesenteric resistance arteries from SHR rats. Data 
are expressed as a percentage of control arteries. D) Effect of U46619 (10 μmol/L), in 
the absence or in the presence of PP1, on mitochondrial membrane potential in aorta 
from SHR rats. Data are expressed as a percentage of control arteries. **P<0.01, 
***P<0.001 vs control. #P<0.05, ##P<0.01 vs H2O2 or U46619. Number of animals is 
indicated in parenthesis. 
.  
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Figure 6. Representative diagram of the signaling pathways involved in the contractile 
response induced by H2O2 in mesenteric resistance arteries from Wistar-Kyoto (WKY) 
and spontaneously hypertensive (SHR) rats. In WKY, H2O2 contractile response is 
mediated by c-Src dependent TXA2 production that further activates c-Src. In arteries 
from SHR c-Src participates in H2O2-induced TXA2 release which further activates Rho 
Kinase, c-Src and the relationship between mitochondria and NAD(P)H Oxidase to 
mediate contractile effects. In addition, TXA2-independent activation of ERK1/2 by 
H2O2 contributes to H2O2 contraction in SHR trough effects on mitochondria and 
NAD(P)H Oxidase. All together, the greater TXA2 and O2
.- 
production and the different 
signaling pathways involved explain the increase in the contractile response induced by 
H2O2 in hypertension. Furegrelate is inhibitor of TXA2 synthase, PP1 inhibits c-Src, 
PD98059 and U0126 are ERK1/2 MAPK inhibitors, SQ29548 is a TP antagonist, 
Y27632 inhibits Rho Kinase, mito-TEMPO and Rotenone inhibit mitochondrial ROS. 
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